Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 31%
Hold 19%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is a strong and well-established biopharmaceutical company with a diverse portfolio of drugs in various therapeutic areas, including HIV, hepatitis, and oncology. The company's recent acquisition of Pharmasset has expanded its presence in the hepatitis C market, and its latest HIV drug, Yeztugo, has been well-received. With a strong pipeline and strategic partnerships, Gilead is positioned for continued growth and has a solid history of managing patent cliffs. However, competition and pricing pressure in the HIV market, as well as ongoing litigation and potential setbacks in pipeline development, may limit short-term upside for the stock. Overall, Gilead offers a mix of stability and potential for growth, making it a Buy-rated stock.

Bears say

Gilead Sciences is facing competition in both its HIV and HCV franchises, potential pricing pressure, and slower than expected uptake of Yescarta. In addition, potential setbacks in its pipeline, particularly in the oncology space, could also impact the stock's performance. This negative outlook is supported by the possibility of downside risks in the company's financials, with a potential DCF valuation scenario of $80 in a worst-case scenario.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 31% recommend Buy, 19% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $154.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $154.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.